GENOME THERAPEUTICS CORP
10-K405, EX-27, 2000-11-22
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: GENOME THERAPEUTICS CORP, 10-K405, EX-99, 2000-11-22
Next: LEGG MASON VALUE TRUST INC, NSAR-A/A, 2000-11-22



<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000356830
<NAME> GENOME THERAPEUTICS CORP.
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          AUG-31-2000
<PERIOD-START>                             SEP-01-1999
<PERIOD-END>                               AUG-31-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          52,111
<SECURITIES>                                    22,349
<RECEIVABLES>                                      843
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                76,236
<PP&E>                                          27,841
<DEPRECIATION>                                  14,393
<TOTAL-ASSETS>                                  91,336
<CURRENT-LIABILITIES>                           12,517
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         2,226
<OTHER-SE>                                      72,049
<TOTAL-LIABILITY-AND-EQUITY>                    91,336
<SALES>                                              0
<TOTAL-REVENUES>                                26,424
<CGS>                                                0
<TOTAL-COSTS>                                   30,639
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 827
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,816)
<EPS-BASIC>                                      (.14)
<EPS-DILUTED>                                    (.14)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission